Alkermes' Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid detoxification.
Vivitrol is a once-monthly, extended-release injectable medication, used to treat alcohol dependence and opioid dependence.
As measured by the number of opioid-free urine screens, Vivitrol, along with psychosocial treatment, reported prolonged efficacy and safety in a one-year, open-label extension of the six-month pivotal study.
The study also measured opioid craving, improvements in quality of life measures, self-reported opioid use and incidence of physical opioid dependence.
National Institute on Drug Abuse (NIDA) has awarded Small Business Innovation Research Program grant for the clinical development programme of Vivitrol.